Nerandomilast

那米司特

Report date: 2026/05/20 20:02:01
NME

Base Information

Drug NameNerandomilast
Drug Alias NameJascayd博优维BI-1015550BI1015550BI 1015550
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionPhosphodiesterase 4B inhibitors
TargetsPhosphodiesterase 4B
Therapy Area/IndicationsScleroderma, SystemicRenal InsufficiencyIdiopathic Pulmonary Fibrosis +[6] 
Global Approved IndicationsIdiopathic Pulmonary FibrosisLung Diseases, Interstitial
Approved Indications in ChinaIdiopathic Pulmonary Fibrosis
Original Approved Country/TerritoryUnited States
Original Approved Date2025/10/07
Country/TerritoryCzechiaBelgiumBulgaria +[55] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesC.H. Boehringer Sohn Ag & Co. Kg
China Registration ClassN/A

Develop Information

Active CompaniesBoehringer Ingelheim Japan IncC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim Pharma Gmbh & Co Kg +[6] 
Inactive CompaniesN/A
Active IndicationsScleroderma, SystemicRenal InsufficiencyIdiopathic Pulmonary Fibrosis +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG